3 results
Primary Objective:To demonstrate that CHF 1535 twice daily is superior to Formoterol twice daily in terms of COPD exacerbations rate during 48 weeks of treatment and in terms of pulmonary function (change in pre-dose morning FEV1 from baseline to 12…
Primary:• To determine the safety and tolerability of FHD-286 when administered as an oral monotherapy in subjects with metastatic uveal melanoma (UM)• To identify the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of FHD-…
This entry-into-human (EIH) Phase Ia/Ib study aims to establish the safety,pharmacokinetics, immunogenicity, and pharmacodynamics of RO7284755 (alone or incombination with atezolizumab) and to evaluate its anti-tumor activity.